Starboard Acquires Becton Dickinson

This is a news story, published by CNBC, that relates primarily to Becton Dickinson news.

Becton Dickinson news

For more Becton Dickinson news, you can click here:

more Becton Dickinson news

emerging technologies news

For more emerging technologies news, you can click here:

more emerging technologies news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best tech news, business news, entertainment news, and much more. If you like emerging technologies news, you might also like this article about

Becton Dickinson

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other shareholders news, global medical technology company news, emerging technologies news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

MedTech business

CNBC

•

Technology

Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit

Summary

Nutrition label

78% Informative

Becton Dickinson ( BDX ) is a global medical technology company comprised of essentially two businesses.

The company operates two distinct businesses that are at different stages with different growth rates and valuation multiples.

If separated, the Medtech Business should get a 13 -times to 14 -times EBITDA valuation based on its growth, while Life Sciences should receive a valuation north of 20 -times.

If separated, the Medtech Business should get a 13 -times to 14 -times EBITDA valuation based on its growth.

Life Sciences could get a valuation north of 20 -times at the low end of the multiple range.

The real value comes from two separate management teams being able to better focus on and devote resources to their own businesses.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language